Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25042 intravitreal injection solution receives clinical trial approval

date
15:57 20/11/2026
avatar
GMT Eight
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SQ-25042 intravitreal injection solution. SQ-25042 intravitreal injection solution is a fusion protein independently developed by the company and is a Class 1 innovative therapeutic biologic product. It is intended clinically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO).
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SQ-25042 intravitreal injection solution. SQ-25042 intravitreal injection solution is a fusion protein independently developed by the company and is a Class 1 innovative therapeutic biologic product. It is intended for clinical use in the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion (RVO).